<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03974139</url>
  </required_header>
  <id_info>
    <org_study_id>RC-P0054</org_study_id>
    <nct_id>NCT03974139</nct_id>
  </id_info>
  <brief_title>Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients</brief_title>
  <acronym>LEPTOB</acronym>
  <official_title>Study of the Communication of the Hypothalamus With the Periphery: Impact of Metformin on Leptin Transport in the Cerebrospinal Fluid of Obese Patients. A Monocentric Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lille Catholic University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Arras</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lille Catholic University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity, a major health problem, is gradually transforming into a global epidemic. The&#xD;
      current obesity treatment with long term efficacy is the bariatric surgery, however, the&#xD;
      operative risk of this procedure is high and the post-operative iotrogeny may be important.&#xD;
      Obesity is most often associated to the feeding behavior which depends on hypothalamic&#xD;
      integration of peripheral signals such as leptin and glucose. High levels of circulating&#xD;
      leptin are detected in obese patients. These elevated leptin levels fail to reduce appetite&#xD;
      or increase energy expenditure. The mechanism underlying this non-integration of peripheral&#xD;
      signals remains to be identified. The ratio of leptin levels in the cereprospinal fluid (CSF)&#xD;
      and in the periphery is drastically decreased in obese patients when compared to lean&#xD;
      individuals, therefore a defective transport of circulating leptin into the brain via the CSF&#xD;
      is maybe linked to obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that the alteration of leptin transport into the CSF of obese patients could&#xD;
      be modulated by drugs such as metformin which is widely used worldwide to treat diabetes.&#xD;
      This study is monocentric, prospective, one-arm type and interventional. The main objective&#xD;
      isto evaluate the impact of metformin on the transport of leptin into the CSF of obese&#xD;
      patients.&#xD;
&#xD;
      We propose to show a variation of CSF leptin / serum leptin before and after metformin&#xD;
      treatment and study its association with changes in hypothalamic metabolic activity,&#xD;
      cognitive and appetite-related behaviors and ratio of other metabolic signals. This would&#xD;
      support the hypothesis of modulation of resistance to peripheral leptin by metformin and thus&#xD;
      uncover a new indication for metformin treatment towards the management of obesity.&#xD;
&#xD;
      For this purpose, volunteers will be subjected to blood sampling via venipuncture, CSF&#xD;
      collection via lumbar puncture, MRI assessments and questionnaires (cognitive tests, food&#xD;
      survey and feeding behavior) before and after a 3-month metformin treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebrospinal fluid /plasma leptin ratio</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cerebrospinal fluid /plasma glucose ratio</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrospinal fluid /plasma glucagon like peptide 1 (GLP1) ratio</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrospinal fluid /plasma insulin ratio</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrospinal fluid /plasma ghrelin ratio</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid levels of Agouti-Related Peptide (AgRP)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of Agouti-Related Peptide (AgRP)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid levels of proopiomelanocortin (POMC)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of proopiomelanocortin (POMC)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid levels of neuropeptide Y (NPY)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of neuropeptide Y (NPY)</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid levels of leptin soluble receptor</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of leptin soluble receptor</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent diffusion coefficient (ADC)</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue, and is commonly clinically calculated using Magnetic resonance imaging (MRI). An ADC of a tissue is expressed in units of mm2/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic concentration of N-acetyl-aspartate (NAA)</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This concentration will be measure by spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic concentration of creatine</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This concentration will be measure by spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic concentration of Choline</measure>
    <time_frame>3 months</time_frame>
    <description>This concentration will be measure by spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic concentration of Glutamine / glutamate</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This concentration will be measure by spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypothalamic concentration of gamma-aminobutyric acid (GABA)</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This concentration will be measure by spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>at day 0, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of body fat</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This parameter will measure by bioelectrical impedance analysis (BIA). A weak electric current flows through the body and the voltage is measured in order to calculate impedance (resistance) of the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat free mass (Kg)</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This parameter will measure by bioelectrical impedance analysis (BIA). A weak electric current flows through the body and the voltage is measured in order to calculate impedance (resistance) of the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This parameter will measure by indirect calorimetry (kCal / 24h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the Three Factor Eating Questionnaire (TFEQ)</measure>
    <time_frame>3 months</time_frame>
    <description>The TFEQ contains 51 items and measures three dimensions of eating behavior:&#xD;
cognitive restraint of eating' (Factor I - 21 items)&#xD;
disinhibition (Factor II - 16 items)&#xD;
hunger (Factor III - 14 items)&#xD;
Each item scores either 0 or 1 point. The minimum score for factors I-II-III is therefore 0-0-0, the possible maximum score 21-16-14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of the Dutch Eating Behaviour Questionnaire (DEBQ)</measure>
    <time_frame>at day 0, 3 months</time_frame>
    <description>This is a 33-item self-report questionnaire to assess three distinct eating behaviors in adults: (1) emotional eating, (2) external eating, and (3) restrained eating. Items on the DEBQ range from 1 (never) to 5 (very often), with higher scores indicating greater endorsement of the eating behavior.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Obesity Without Type 2 Diabetes, With BMI&gt;30</condition>
  <arm_group>
    <arm_group_label>Obese patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with body mass index &gt;30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Oral Tablet</intervention_name>
    <description>Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day</description>
    <arm_group_label>Obese patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults between 18 and 40 years old&#xD;
&#xD;
          -  Body mass index &gt;30&#xD;
&#xD;
          -  For childbearing age women: use of an effective contraceptive method for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Patients willing to participate in the study and who have signed the informed consent&#xD;
             form&#xD;
&#xD;
          -  Patients with health insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic obesity&#xD;
&#xD;
          -  Patients already treated with metformin&#xD;
&#xD;
          -  Type 2 diabetes defined by 2 fasting blood glucose &gt;1,26g/L or blood glucose &gt;2 g/L at&#xD;
             120 min of oral glucose tolerance test with 75 g of glucose&#xD;
&#xD;
          -  Glucose intolerance (fasting blood glucose between 1,10 g/L and 1,26 g/L or blood&#xD;
             glucose between 1,40 g/L and 2g/L at 120 minutes of oral glucose tolerance test with&#xD;
             75 g of glucose)Active neoplastic pathology, diagnosed &lt; 5 years, or in treatment&#xD;
&#xD;
          -  Neurological pathology (demyelinating, tumor, vascular)&#xD;
&#xD;
          -  Adipose tissue pathology (lipodystrophy)&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Contraindication to metformin&#xD;
&#xD;
          -  Lumbar puncture contraindication&#xD;
&#xD;
          -  MRI contraindication&#xD;
&#xD;
          -  Person unable to consent, or benefiting from a legal protection regime&#xD;
             (guardianship/curatorship/guardianship of justice)&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Contra-indication to impedance measurement&#xD;
&#xD;
          -  Contraindication to indirect calorimetry: claustrophobia&#xD;
&#xD;
          -  Taking a psychotropic drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Prévot, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Florent, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier d'Arras, INSERM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie Lansiaux, MD, PhD</last_name>
    <phone>0033320225741</phone>
    <email>lansiaux.amelie@ghcl.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melody Plets, MSc</last_name>
    <phone>0033320225733</phone>
    <email>plets.melody@ghicl.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier d'Arras</name>
      <address>
        <city>Arras</city>
        <zip>62022</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Florent, MD, MSc, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>leptin</keyword>
  <keyword>cerebrospinal fluid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

